Guido Koopmans
Chief Scientific Officer Algiax Pharmaceuticals
Dr. Guido Koopmans is a neuroscientist and Co-founder of Algiax Pharmaceuticals with over 15 years of experience in pain research and clinical development. As Chief Scientific Officer at Algiax Pharmaceuticals, he’s led the development of AP-325, a novel dual-target pain therapeutic now in Phase II trials. He’s passionate about translating neuroscience into real-world therapies and thrives at the intersection of science, strategy, and innovation.
Seminars
Wednesday 28th January 2026
Rethinking Pain: A Dual-Target Approach Leveraging GABA-A & DHODH Modulation
8:00 am
- Gain insights from Phase 2a clinical data of AP-325 in neuropathic pain and its impact on patient outcomes
- Understand the next steps in clinical development and how this therapy could shape future treatment strategies
- Explore the potential of dual-target mechanisms to deliver more effective, long-term pain relief
